Apellis Pharmaceuticals Inc

NASDAQ:APLS   3:59:46 PM EDT
47.17
+0.69 (+1.48%)
Earnings Announcements

Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses & Quality-Of-Life Improvements vs C5 Inhibitors For Pnh

Published: 12/07/2020 19:27 GMT
Apellis Pharmaceuticals Inc (APLS) - Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-life Improvements Compared to C5 Inhibitors for Pnh.
Apellis Pharmaceuticals Inc - Quality-of-life Substantially Improved for Pegcetacoplan-treated Patients, Reaching Near-normal Levels.
Apellis - 70.7% of Patients Treated With Pegcetacoplan Versus 5.1% of Eculizumab-treated Patients Achieved Good, Major, Complete Hematologic Response.
Apellis - Matching-adjusted Indirect Comparison Suggests 76% More Patients on Pegcetacoplan Achieved Hemoglobin Stabilization Compared to Ravulizumab.
Apellis Pharmaceuticals Inc - 71% More Patients on Pegcetacoplan Were Transfusion Free Compared to Ravulizumab.
Revenue is expected to be $1.43 Million
Adjusted EPS is expected to be -$1.72

Next Quarter Revenue Guidance is expected to be $16.36 Million
Next Quarter EPS Guidance is expected to be -$1.55

More details on our Analysts Page.